• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gynecologic Oncology Reports >Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2eu with trastuzumab emtansine (TDM-1)
【24h】

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2eu with trastuzumab emtansine (TDM-1)

机译：曲妥珠单抗Emtansine（TDM-1）过度表达HER2 / neu的转移性，放射线/化疗耐药性子宫浆液性癌的消退

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background The management of uterine-serous-carcinoma (USC) no longer amenable to treatment with surgery, radiation and/or chemotherapy remains dismal. Alternative therapeutic options are desperately needed. Case We describe the case of a heavily pretreated 74-year-old patient with a recurrent USC overexpressing HER2eu at 3 + level by IHC treated with the anti-HER2eu antibody-drug-conjugate (ADC) trastuzumab-emtansine (TDM-1-Kadcyla-Genentech/Roche). She experienced a remarkable clinical response to TDM-1 with a complete resolution of a large metastatic, radiation/chemotherapy resistant tumor deposit in her abdominal wall muscle confirmed by multiple CAT scans and a prolonged systemic control of her disease. Conclusion TDM-1 may represent a novel treatment option for recurrent/metastatic HER2eu-positive USC patients refractory to salvage-treatment. Highlights ? USC patients have limited therapeutic options when the disease becomes resistant to chemotherapy. ? About 35% of USC overexpress the HER2eu receptor at 3 + level by IHC and/or are c-erbB2 gene amplified. ? Trastuzumab emtansine (T-DM1, Kadcyla) is a novel antibody-drug conjugate. ? T-DM1 may represent a novel treatment modality in USC patients with recurrent, HER2eu + disease.
机译：背景技术子宫浆液性癌（USC）的治疗不再适合通过手术，放疗和/或化学疗法进行治疗。迫切需要替代疗法。案例我们描述了一个经过严格治疗的74岁患者，该患者通过IHC用抗HER2 / neu抗体-药物-缀合物（ADC）曲妥珠单抗-丹参胺（TDM）治疗的USC反复超表达HER2 / neu的3+水平-1-Kadcyla-Genentech / Roche）。她经历了对TDM-1的显着临床反应，通过多次CAT扫描和对疾病的长期系统控制证实了腹壁肌中大量转移性，放射线/化疗耐药性肿瘤沉积的完全解决。结论TDM-1可能为难治性治疗的复发/转移性HER2 / neu阳性USC患者提供了一种新的治疗选择。强调 ？当疾病对化学疗法产生抗药性时，USC患者的治疗选择有限。 ？大约35％的USC通过IHC在3 +水平上过表达HER2 / neu受体和/或被c-erbB2基因扩增。 ？曲妥珠单抗Emtansine（T-DM1，Kadcyla）是新型抗体-药物偶联物。 ？ T-DM1可能代表复发性HER2 / neu +疾病的USC患者的新型治疗方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号